Alpha 2.0
Login Register
» Authors » Victoria M Long

Victoria M Long

Explore the profile of Victoria M Long including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 71
Followers 0
Related Specialties
Pharmacology
Psychiatry
Neurology
Top 10 Co-Authors
Lorenzo Leggio
Carolina L Haass-Koffler
Robert M Swift
Kimberly Goodyear
George A Kenna
Roberto Cacciaglia
Antonella Loche
Harrison H Tran
Molly Magill
Paul M Wallace
Published In
Drug Alcohol Depend
J Psychopharmacol
Eur J Pharm Sci
Neuropharmacology
Data Brief
Affiliations
Soon will be listed here.
Recent Articles
1.
Differences in Sociodemographic and Alcohol-Related Clinical Characteristics Between Treatment Seekers and Nontreatment Seekers and Their Role in Predicting Outcomes in the COMBINE Study for Alcohol Use Disorder
Haass-Koffler C, Piacentino D, Li X, Long V, Lee M, Swift R, et al.
Alcohol Clin Exp Res . 2020 Sep; 44(10):2097-2108. PMID: 32997422
Background: One of the challenges in early-stage clinical research aimed at developing novel treatments for alcohol use disorder (AUD) is that the enrolled participants are heavy drinkers, but do not...
2.
Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind, placebo-controlled human laboratory study
Haass-Koffler C, Long V, Farokhnia M, Magill M, Kenna G, Swift R, et al.
Neuropharmacology . 2019 Jul; 158:107711. PMID: 31310775
Increasing evidence supports the role of appetite-regulating hormones, including ghrelin, in alcohol use disorder (AUD). Effects of ghrelin administration on cortisol and aldosterone, two hormones known to influence the development...
3.
Administration of the metabotropic glutamate receptor subtype 5 allosteric modulator GET 73 with alcohol: A translational study in rats and humans
Haass-Koffler C, Goodyear K, Loche A, Long V, Lobina C, Tran H, et al.
J Psychopharmacol . 2018 Jan; 32(2):163-173. PMID: 29361897
Preclinical work suggests that GET 73 (N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide), a novel metabotropic glutamate receptor subtype 5 negative allosteric modulator, may represent a novel pharmacological treatment for alcohol use disorder. Two independent experiments...
4.
Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters
Haass-Koffler C, Goodyear K, Long V, Tran H, Loche A, Cacciaglia R, et al.
Data Brief . 2017 Dec; 15:407-413. PMID: 29214202
The data in this article outline the methods used for the administration of GET 73 in the first time-in-human manuscript entitled "Phase I randomized clinical trial for the safety, tolerability...
5.
A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers
Haass-Koffler C, Goodyear K, Long V, Tran H, Loche A, Cacciaglia R, et al.
Eur J Pharm Sci . 2017 Aug; 109:78-85. PMID: 28778464
Preclinical work suggests that the metabotropic glutamate receptor subtype 5 (mGlu5) may represent a novel target to treat neuropsychiatric disorders, including alcohol use disorder and obesity. The goal of this...
6.
Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin
Haass-Koffler C, Goodyear K, Zywiak W, Magill M, Eltinge S, Wallace P, et al.
Drug Alcohol Depend . 2017 May; 177:23-28. PMID: 28551590
Background: Preclinical and clinical research suggest that the α receptor antagonist prazosin reduces alcohol consumption. Furthermore, clinical studies indicate a role for prazosin in treating Post-Traumatic Stress Disorder (PTSD) symptoms...